Monoclonal antibodies against the vascular endothelial growth factor (VEGF) or, in patients with KRAS/NRAS wild-type tumours, against the epidermal growth factor receptor (EGFR) are commonly added to chemotherapy in mCRC. This evidence concerns the gene NRAS and neoplasm.